JP5703466B2 - キナーゼ阻害薬およびその使用 - Google Patents

キナーゼ阻害薬およびその使用 Download PDF

Info

Publication number
JP5703466B2
JP5703466B2 JP2010520314A JP2010520314A JP5703466B2 JP 5703466 B2 JP5703466 B2 JP 5703466B2 JP 2010520314 A JP2010520314 A JP 2010520314A JP 2010520314 A JP2010520314 A JP 2010520314A JP 5703466 B2 JP5703466 B2 JP 5703466B2
Authority
JP
Japan
Prior art keywords
kinase
amino acid
peptide
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010520314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535508A (ja
JP2010535508A5 (OSRAM
Inventor
アリッサ パニチ
アリッサ パニチ
ブランドン シール
ブランドン シール
シー． ウォード，ブライアン
シー． ウォード，ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2010535508A publication Critical patent/JP2010535508A/ja
Publication of JP2010535508A5 publication Critical patent/JP2010535508A5/ja
Application granted granted Critical
Publication of JP5703466B2 publication Critical patent/JP5703466B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010520314A 2007-08-07 2008-08-07 キナーゼ阻害薬およびその使用 Expired - Fee Related JP5703466B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96394107P 2007-08-07 2007-08-07
US60/963,941 2007-08-07
US99497007P 2007-09-24 2007-09-24
US60/994,970 2007-09-24
PCT/US2008/072525 WO2009021137A2 (en) 2007-08-07 2008-08-07 Kinase inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2010535508A JP2010535508A (ja) 2010-11-25
JP2010535508A5 JP2010535508A5 (OSRAM) 2014-05-15
JP5703466B2 true JP5703466B2 (ja) 2015-04-22

Family

ID=40342047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520314A Expired - Fee Related JP5703466B2 (ja) 2007-08-07 2008-08-07 キナーゼ阻害薬およびその使用

Country Status (6)

Country Link
US (2) US8741849B2 (OSRAM)
EP (1) EP2185698B1 (OSRAM)
JP (1) JP5703466B2 (OSRAM)
DK (1) DK2185698T3 (OSRAM)
ES (1) ES2547229T3 (OSRAM)
WO (1) WO2009021137A2 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
ES2476842T3 (es) * 2007-01-10 2014-07-15 Purdue Research Foundation Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
CA2741302C (en) * 2008-10-20 2017-02-28 Moerae Matrix, Inc. Mapkap kinase inhibitor polypeptide for treating or preventing adhesions
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
CN108014340A (zh) * 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN102949722A (zh) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 基于p38抑制剂和细胞生长因子的新颖药物组合物
US10252984B2 (en) 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
EP2773777B1 (en) * 2011-10-31 2020-05-13 University of Utah Research Foundation Genetic alterations in glioblastoma
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2014160364A1 (en) * 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
HK1216152A1 (zh) 2013-04-11 2016-10-21 Vanderbilt University 複合體
GB201314610D0 (en) 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
CN103739678B (zh) * 2013-12-31 2015-09-02 刘培臣 抑制粘附斑激酶多肽及其应用
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
WO2015164411A2 (en) 2014-04-21 2015-10-29 Mayo Foundation For Medical Education And Research Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
EP3177366A4 (en) * 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
JP2018501201A (ja) 2014-11-17 2018-01-18 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法
CA2972916A1 (en) 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
JP2018512401A (ja) * 2015-03-12 2018-05-17 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
ES3010661T3 (en) 2016-02-26 2025-04-04 Univ Leland Stanford Junior Pi-kinase inhibitors with anti-infective activity
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11213857B2 (en) 2017-06-06 2022-01-04 Derrick Corporation Method and apparatus for screening
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3100074A1 (en) 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Peptide activating agent
US12134663B2 (en) 2018-05-15 2024-11-05 Interk Peptide Therapeutics Limited Cationic peptides for activating Lck
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CN113227094B (zh) * 2018-09-12 2025-02-11 普渡研究基金会 作为激酶抑制剂的炔基烟酰胺化合物
US20220062243A1 (en) * 2019-01-11 2022-03-03 Jeffrey S. Glenn P14-Kinase Inhibitors with Anti-Cancer Activity
EP3941909A4 (en) 2019-03-21 2023-01-25 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors and methods of using the same
EP4058470A4 (en) * 2019-11-15 2024-02-28 The Regents of the University of Colorado, A Body Corporate Novel peptide compositions and methods of treating neurological injury
CN114605497B (zh) * 2021-02-10 2023-04-28 北京欣安诚科技有限公司 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
CN115976033B (zh) * 2022-12-14 2024-05-17 西南大学 瓜实蝇tssk1和tssk3基因及其应用
WO2025151669A1 (en) * 2024-01-10 2025-07-17 President And Fellows Of Harvard College Clk2 inhibition as a radiation countermeasure

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) * 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) * 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) * 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
FI88112C (fi) * 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
CA2080224A1 (en) * 1990-04-18 1991-10-19 Jindrich Kopecek Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
DE69333955D1 (de) 1992-04-24 2006-02-02 Stanford Res Inst Int Targeting homologer sequenzen in eukaryotenzellen
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CA2178729A1 (en) * 1993-12-09 1995-06-15 Eric B. Kmiec Compounds and methods for site-directed mutations in eukaryotic cells
JP2002505077A (ja) * 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
JP2002510336A (ja) * 1998-04-11 2002-04-02 エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
MXPA03001406A (es) * 2000-08-15 2004-05-04 Surmodics Inc Matriz de incorporacion de medicamento.
US7858094B2 (en) * 2000-12-08 2010-12-28 Geneprint Corporation TREM-1 splice variant for use in modifying immune responses
AU2002226061B2 (en) * 2001-01-18 2007-08-02 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta PKC
DE10118774A1 (de) 2001-04-17 2002-10-31 Jerini Ag Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
EP1523323B1 (en) * 2001-08-23 2013-07-24 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20050153372A1 (en) * 2002-02-21 2005-07-14 Paul Greengard Compositions and method for regulation of calcium-dependent signaling in brain
US20040005686A1 (en) 2002-03-07 2004-01-08 Pharmacia Corporation Crystalline structure of human MAPKAP kinase-2
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
CN1735687A (zh) 2002-08-02 2006-02-15 惠氏公司 Mk2相互作用蛋白
CA2510298A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
DK1808179T3 (da) * 2003-02-21 2010-04-12 Univ Arizona Anvendelse af HSP20 til fremme af sårheling og/eller til formindskelse af ardannelse
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
JP2007508823A (ja) 2003-10-17 2007-04-12 アリゾナ ボード オブ リージェンツ 新規な熱ショックタンパク質２０関連ポリペプチドおよびその使用
EP2302393A1 (en) 2004-05-21 2011-03-30 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
EP1771183B1 (en) * 2004-07-23 2014-09-03 The Trustees of The University of Pennsylvania Antimicrobial copolymers and uses thereof
CA2586987A1 (en) * 2004-11-12 2006-05-18 Massachusetts Institute Of Technology Methods and compositions for treating cellular proliferative diseases
US8008093B2 (en) 2004-12-02 2011-08-30 The University Of North Carolina At Chapel Hill Inhibition of Hsp27 phosphorylation for the treatment of blistering disorders
WO2006105278A2 (en) * 2005-03-29 2006-10-05 The Regents Of The University Of California Controlling stem cell destiny destiny with tunable network
CN101232895B (zh) * 2005-04-15 2014-06-04 亚利桑那癌症治疗公司 用于治疗转移性癌症的治疗肽
SI1948259T1 (sl) * 2005-10-26 2017-07-31 Genesis Technologies Limited Acelularni bioabsorbljivi tkivni regeneracijski matriksi, proizvedeni z inkubiranjem acelularnih proizvodov krvi
CN101426808A (zh) * 2005-11-01 2009-05-06 亚利桑那董事会,代表亚利桑那州立大学行事的法人团体 新颖的蛋白质转导结构域及其应用
WO2007062060A2 (en) * 2005-11-22 2007-05-31 Ted Reid Methods and compositions using substance p to promote wound healing
JP5048772B2 (ja) 2006-07-12 2012-10-17 ジ アリゾナ ボード オブ レジェンツ，ア ボディ コーポレイト アクティング フォア アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティ 線維性疾患及びケロイドを治療及び抑制する方法
ES2476842T3 (es) 2007-01-10 2014-07-15 Purdue Research Foundation Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
WO2009123759A2 (en) 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions
CA2741302C (en) 2008-10-20 2017-02-28 Moerae Matrix, Inc. Mapkap kinase inhibitor polypeptide for treating or preventing adhesions
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20110288036A1 (en) * 2010-05-24 2011-11-24 Cynthia Lander Methods for Treating or Preventing Vascular Graft Failure
CN108014340A (zh) 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法

Also Published As

Publication number Publication date
EP2185698A2 (en) 2010-05-19
HK1144306A1 (zh) 2011-02-11
US20090149389A1 (en) 2009-06-11
ES2547229T3 (es) 2015-10-02
US8741849B2 (en) 2014-06-03
EP2185698A4 (en) 2012-03-28
US20140342993A1 (en) 2014-11-20
DK2185698T3 (en) 2015-07-27
WO2009021137A2 (en) 2009-02-12
JP2010535508A (ja) 2010-11-25
US9447158B2 (en) 2016-09-20
WO2009021137A3 (en) 2009-07-09
US20130184221A9 (en) 2013-07-18
EP2185698B1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
JP5703466B2 (ja) キナーゼ阻害薬およびその使用
Li et al. The cyclopeptide astin C specifically inhibits the innate immune CDN sensor STING
Jobson et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
EP2378875B1 (en) Cell-permeant peptide-based inhibitor of kinases
Hochwald et al. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer
US20220313700A1 (en) Methods for treating map3k8 positive cancers
US9999655B2 (en) Use of MKS inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
KR101585702B1 (ko) 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성
AU2007233784A1 (en) Use of a kinase inhibitor for the treatment of particular resistant tumors
US20060115453A1 (en) Methods and compositions for treating cellular proliferative diseases
JP2005040137A (ja) Ｊｎｋを標的化することによりプログラム細胞死またはアポトーシスをブロックする新規な因子の同定
CN111603466B (zh) 一种乙酮类化合物在制备治疗肿瘤药物中的应用
Zhao et al. TEIF associated centrosome activity is regulated by EGF/PI3K/Akt signaling
US20190022176A1 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
HK1144306B (en) Kinase inhibitors and uses thereof
Ye et al. Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumor
Yan et al. Repurposed doxepin targeting host AXL kinase to disrupt viral 2C-mediated immune evasion in Coxsackievirus B infection
Del Rosario et al. MK2 Expression Promotes Non-Small Cell Lung Cancer Cell Death and Predicts Survival
AU2016201861B2 (en) Cell-permeant peptide-based inhibitor of kinases
Galembikova et al. Effect of pivaloyl-substituted pyrrole containing heterocyclic compounds on DNA repair pathways in Ewing sarcoma cells
Sharma Signaling Pathways and Novel Inhibitors in Chronic Lymphocytic Leukemia
JP2007529540A (ja) 混合系統キナーゼの阻害およびそのための用途
HK1228750A1 (en) Cell-permeant peptide-based inhibitor of kinases
HK1163449B (en) Cell-permeant peptide-based inhibitor of kinases
HK1163449A (en) Cell-permeant peptide-based inhibitor of kinases

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20101014

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131030

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141029

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

R150 Certificate of patent or registration of utility model

Ref document number: 5703466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees